NASDAQ:BOLT

Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis

Bolt Biotherapeutics logo
$5.06 -0.04 (-0.78%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$5.09 +0.03 (+0.59%)
As of 08:58 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Bolt Biotherapeutics Stock (NASDAQ:BOLT)

Advanced

Key Stats

Today's Range
$5.06
▼
$5.30
50-Day Range
$3.35
▼
$6.59
52-Week Range
$3.10
▼
$7.78
Volume
35,614 shs
Average Volume
758,324 shs
Market Capitalization
$13.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.50
Consensus Rating
Hold

Company Overview

Bolt Biotherapeutics is a clinical-stage biotechnology company based in Redwood City, California. It develops immunotherapies designed to direct the body’s immune system against cancer.

The company’s Boltbody platform is designed to pair tumor-targeting antibodies with immune-stimulating components. Its pipeline has included BDC-3042, an investigational antibody intended to activate macrophages, immune cells that can help recognize and attack tumors.

Bolt has also developed BDC-1001, an investigational HER2-targeting immune-stimulating antibody conjugate. The company’s programs are in clinical development, and its therapies are not established treatments for cancer.

AI Generated. May Contain Errors.

Bolt Biotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
66th Percentile Overall Score

BOLT MarketRank™: 
3.295485824385 of 5 stars

Bolt Biotherapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 256th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bolt Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Bolt Biotherapeutics has a consensus price target of $14.50, representing about 186.6% upside from its current price of $5.06.

  • Amount of Analyst Coverage

    Bolt Biotherapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Bolt Biotherapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bolt Biotherapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bolt Biotherapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Bolt Biotherapeutics has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.72% of the float of Bolt Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Bolt Biotherapeutics has a short interest ratio ("days to cover") of 0.04, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bolt Biotherapeutics has recently increased by 200.82%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Bolt Biotherapeutics does not currently pay a dividend.

  • Dividend Growth

    Bolt Biotherapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Bolt Biotherapeutics has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Bolt Biotherapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    3 people have searched for BOLT on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $500,563.00 in company stock, which represents 3.7902% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Bolt Biotherapeutics insiders have bought 389.97% more of their company's stock than they have sold. Specifically, they have bought $628,924.00 in company stock and sold $128,361.00 in company stock.

  • Percentage Held by Insiders

    9.40% of the stock of Bolt Biotherapeutics is held by insiders.

  • Percentage Held by Institutions

    86.70% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bolt Biotherapeutics' insider trading history.
Receive BOLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BOLT Stock News Headlines

My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
See More Headlines

BOLT Stock Analysis - Frequently Asked Questions

Bolt Biotherapeutics' stock was trading at $5.47 at the beginning of 2026. Since then, BOLT shares have decreased by 7.5% and is now trading at $5.06.

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) released its quarterly earnings data on Thursday, November, 12th. The company reported ($2.25) EPS for the quarter, topping analysts' consensus estimates of ($3.68) by $1.43. The firm had revenue of $450 thousand for the quarter, compared to the consensus estimate of $450 thousand. Bolt Biotherapeutics had a negative trailing twelve-month return on equity of 154.11% and a negative net margin of 611.47%.

Bolt Biotherapeutics's stock reverse split on Monday, June 9th 2025.A 1-20 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, June 8th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Bolt Biotherapeutics (BOLT) raised $213 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 11,500,000 shares at $18.00-$19.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO.

Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bolt Biotherapeutics investors own include onsemi (ON), Enterprise Products Partners (EPD), NIO (NIO), Energy Transfer (ET), Achilles Therapeutics (ACHL), Aldeyra Therapeutics (ALDX) and CRISPR Therapeutics (CRSP).

Company Calendar

Last Earnings
11/12/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BOLT
CIK
1641281
Fax
N/A
Employees
23
Year Founded
2015

Price Target and Rating

High Price Target
$22.00
Low Price Target
$7.00
Potential Upside/Downside
+186.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($14.97)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$33.38 million
Net Margins
-611.47%
Pretax Margin
-1,027.93%
Return on Equity
-154.11%
Return on Assets
-57.59%

Debt

Debt-to-Equity Ratio
2.06
Current Ratio
2.05
Quick Ratio
2.61

Sales & Book Value

Annual Sales
$7.70 million
Price / Sales
1.72
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.28 per share
Price / Book
1.54

Miscellaneous

Outstanding Shares
2,610,000
Free Float
2,363,000
Market Cap
$13.21 million
Optionable
Not Optionable
Beta
0.85

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:BOLT) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners